Opendata, web and dolomites

ONCOCHECK

A simple blood test to monitor disease progression in patients undergoing cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ONCOCHECK" data sheet

The following table provides information about the project.

Coordinator
LIFE LENGTH SL 

Organization address
address: CALLE MIGUEL ANGEL 11 2 PLANTA
city: MADRID
postcode: 28010
website: www.lifelength.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://lifelength.com/press/Life_Length_H2020.pdf
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIFE LENGTH SL ES (MADRID) coordinator 50˙000.00

Map

 Project objective

The ultimate objective of the ONCOCHECK project is to bring to the healthcare market a unique solution for cancer monitoring which is a simple blood test that will allow oncologist the evaluation of disease progression in patients affected by the great majority of cancers, with no distinction between haematological of solid tumours. Our test will be based on the determination of telomere length in peripheral blood, which is a cancer biomarker that has been identified in the great majority of cancers. The ONCOCHECK test will offer to the healthcare community a test that is simpler (blood test), less costly (200€/test) and more effective (regular monitoring will lead to improved efficiency) as an alternative to other cancer monitoring alternatives that are expensive (2.000-5.000€), complex (need for specialized and very expensive equipment) and less effective (impossible to be performed regularly) imaging techniques conventionally used in the clinic. Moreover, the great advantage of the ONCOCHECK tests over other newly developed competing blood tests based on validated biomarkers is that ONCOCHECK will serve for monitoring all types of cancer, while competing biomarker based solutions are useful only for a specific cancer/tumour. Therefore, Life Length´s test will offer a universal solution for cancer monitoring, with no competitors offering a similar approach.

Considering that there are more than 35 million of people affected by cancer all over the world and that the ONCOCHECK will serve for monitoring all cancer types, the business opportunity seems unquestionable. Through the ONCOCHECK project, we seek positioning our company as a leading player on the Advanced Next Generation Cancer Diagnostic Market, which is estimated globally at €5.3 billion in 2015 and expected to reach €10 billion by 2019, representing a huge opportunity for us.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOCHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOCHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More